CL2009001358A1 - Compuestos macrociclicos derivados de urea y derivados de sulfamida, inhibidores de la enzima tafia; proceso de preparacion de dichos compuestos; y su uso para la prevencion y tratamiento de trastornos asociados con trombosis, embolias, hipercoagulabilidad o cambios fibroticos. - Google Patents

Compuestos macrociclicos derivados de urea y derivados de sulfamida, inhibidores de la enzima tafia; proceso de preparacion de dichos compuestos; y su uso para la prevencion y tratamiento de trastornos asociados con trombosis, embolias, hipercoagulabilidad o cambios fibroticos.

Info

Publication number
CL2009001358A1
CL2009001358A1 CL2009001358A CL2009001358A CL2009001358A1 CL 2009001358 A1 CL2009001358 A1 CL 2009001358A1 CL 2009001358 A CL2009001358 A CL 2009001358A CL 2009001358 A CL2009001358 A CL 2009001358A CL 2009001358 A1 CL2009001358 A1 CL 2009001358A1
Authority
CL
Chile
Prior art keywords
compounds
hypercoagulability
thrombosis
prevention
disorders associated
Prior art date
Application number
CL2009001358A
Other languages
English (en)
Inventor
Mark Broenstrup
Andreas Evers
Cristopher Kallus
Anja Globisch
Herman Schreuder
Michael Wagner
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2009001358A1 publication Critical patent/CL2009001358A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA INVENCIÓN SE REFIERE A COMPUESTOS DE FÓRMULA I:<br /> QUE SON INHIBIDORES DE LA FIBRINOLISIS ACTIVABLE POR TROMBINA ACTIVADA. LOS COMPUESTOS DE LA FÓRMULA I<br /> SON ADECUADOS PARA LA FABRICACIÓN DE MEDICAMENTOS PARA LA PROFILAXIS, PREVENCIÓN SECUNDARIA Y<br /> TERAPIA DE UNO O MÁS TRASTORNOS ASOCIADOS CON TROMBOSIS, EMBOLIAS, HIPERCOAGULABILIDAD O CAMBIOS<br /> FIBRÓTICOS.<br /> TAMBIÉN LA INVENCIÓN SE REFIERE PROCESOS DE PREPARACIÓN DE DICHOS COMPUESTOS Y A USOS<br /> PARA LA PREVENCIÓN Y TRATAMIENTO DE TRASTORNOS ASOCIADOS CON TROMBOSIS, EMBOLIAS,<br /> HIPERCOAGULABILIDAD O CAMBIOS FIBRÓTICOS.<br />  
CL2009001358A 2008-06-06 2009-06-04 Compuestos macrociclicos derivados de urea y derivados de sulfamida, inhibidores de la enzima tafia; proceso de preparacion de dichos compuestos; y su uso para la prevencion y tratamiento de trastornos asociados con trombosis, embolias, hipercoagulabilidad o cambios fibroticos. CL2009001358A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290520 2008-06-06

Publications (1)

Publication Number Publication Date
CL2009001358A1 true CL2009001358A1 (es) 2009-11-27

Family

ID=39800716

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001358A CL2009001358A1 (es) 2008-06-06 2009-06-04 Compuestos macrociclicos derivados de urea y derivados de sulfamida, inhibidores de la enzima tafia; proceso de preparacion de dichos compuestos; y su uso para la prevencion y tratamiento de trastornos asociados con trombosis, embolias, hipercoagulabilidad o cambios fibroticos.

Country Status (35)

Country Link
US (5) US8580777B2 (es)
EP (1) EP2300462B1 (es)
JP (1) JP5531011B2 (es)
KR (1) KR101673886B1 (es)
CN (1) CN102056922B (es)
AR (1) AR072007A1 (es)
AU (1) AU2009254257B2 (es)
BR (1) BRPI0913349A2 (es)
CA (1) CA2726554C (es)
CL (1) CL2009001358A1 (es)
CO (1) CO6321271A2 (es)
CR (1) CR11807A (es)
CY (1) CY1115604T1 (es)
DK (1) DK2300462T3 (es)
DO (1) DOP2010000363A (es)
EC (1) ECSP10010655A (es)
ES (1) ES2494390T3 (es)
HK (1) HK1152936A1 (es)
HN (1) HN2010002558A (es)
HR (1) HRP20140787T1 (es)
IL (1) IL209772A (es)
MA (1) MA32322B1 (es)
MX (1) MX2010012793A (es)
NI (1) NI201000203A (es)
NZ (1) NZ589671A (es)
PL (1) PL2300462T3 (es)
PT (1) PT2300462E (es)
RU (1) RU2502736C2 (es)
SI (1) SI2300462T1 (es)
SV (1) SV2010003747A (es)
TW (1) TWI455928B (es)
UA (1) UA104002C2 (es)
UY (1) UY31868A (es)
WO (1) WO2009146802A1 (es)
ZA (1) ZA201007719B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102056922B (zh) 2008-06-06 2013-11-20 赛诺菲-安万特 作为tafia抑制剂的大环脲和磺酰胺衍生物
EP2321301A4 (en) 2008-06-23 2011-09-28 Astrazeneca Ab NOVEL HETEROCYCLIC CARBOXAMIDES AS THROMBIN INHIBITORS
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
HUE034118T2 (en) * 2012-03-06 2018-01-29 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
WO2014198620A1 (en) * 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
UY35809A (es) * 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
CN103755852B (zh) * 2013-12-18 2015-12-09 湖北大学 线型聚苯乙烯支载(4s)-(4’-氧苄基)-2-正丁基环磺酰胺及其制备方法和用途
CN106631832A (zh) * 2016-10-08 2017-05-10 帕潘纳(北京)科技有限公司 一种氨基醚类化合物的制备方法
US10411291B2 (en) * 2017-03-22 2019-09-10 Nanotek Instruments, Inc. Multivalent metal ion battery having a cathode layer of protected graphitic carbon and manufacturing method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667995B2 (en) 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US5888971A (en) * 1996-02-20 1999-03-30 Ortho Pharmaceutical Corporation, Inc. Macrocyclic peptides useful in the treatment of thrombin related disorders
DE69824433D1 (en) 1997-08-28 2004-07-15 Biovitrum Ab Proteintyrosinphosphatase inhibitoren
US6124278A (en) * 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
US6482921B1 (en) 1999-01-28 2002-11-19 Essential Therapeutics, Inc. Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
EP1130022B1 (en) * 2000-02-29 2009-07-22 Universita Degli Studi di Firenze 3-Aza-6,8-dioxabicyclo[3.2.1]octanes and analogues and combinatorial libraries containing them
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla
KR20090087044A (ko) 2006-12-06 2009-08-14 사노피-아벤티스 ＴＡＦＩａ 억제제로서의 요소 및 설파미드 유도체
CN102056922B (zh) 2008-06-06 2013-11-20 赛诺菲-安万特 作为tafia抑制剂的大环脲和磺酰胺衍生物

Also Published As

Publication number Publication date
AU2009254257B2 (en) 2013-11-21
EP2300462A1 (de) 2011-03-30
UA104002C2 (ru) 2013-12-25
CR11807A (es) 2011-02-16
DOP2010000363A (es) 2010-12-15
US9126955B2 (en) 2015-09-08
NZ589671A (en) 2012-03-30
WO2009146802A1 (de) 2009-12-10
CY1115604T1 (el) 2017-01-04
SI2300462T1 (sl) 2014-09-30
IL209772A0 (en) 2011-02-28
DK2300462T3 (da) 2014-08-18
US20110178130A1 (en) 2011-07-21
CA2726554C (en) 2015-02-24
US8722655B2 (en) 2014-05-13
KR101673886B1 (ko) 2016-11-08
US20140206760A1 (en) 2014-07-24
MX2010012793A (es) 2010-12-14
CN102056922B (zh) 2013-11-20
NI201000203A (es) 2011-09-29
IL209772A (en) 2016-04-21
JP2011521981A (ja) 2011-07-28
UY31868A (es) 2010-01-05
KR20110020795A (ko) 2011-03-03
HRP20140787T1 (hr) 2014-11-21
RU2502736C2 (ru) 2013-12-27
US20160024033A1 (en) 2016-01-28
SV2010003747A (es) 2011-03-15
PT2300462E (pt) 2014-08-05
AU2009254257A1 (en) 2009-12-10
PL2300462T3 (pl) 2014-10-31
ECSP10010655A (es) 2011-01-31
MA32322B1 (fr) 2011-05-02
AR072007A1 (es) 2010-07-28
CO6321271A2 (es) 2011-09-20
ZA201007719B (en) 2011-07-27
US20140039011A1 (en) 2014-02-06
TWI455928B (zh) 2014-10-11
CN102056922A (zh) 2011-05-11
ES2494390T3 (es) 2014-09-15
US9309207B2 (en) 2016-04-12
BRPI0913349A2 (pt) 2015-11-24
CA2726554A1 (en) 2009-12-10
US8580777B2 (en) 2013-11-12
US9688645B2 (en) 2017-06-27
TW201008917A (en) 2010-03-01
EP2300462B1 (de) 2014-05-21
HK1152936A1 (en) 2012-03-16
RU2010154089A (ru) 2012-07-20
US20160251324A1 (en) 2016-09-01
HN2010002558A (es) 2012-08-28
JP5531011B2 (ja) 2014-06-25

Similar Documents

Publication Publication Date Title
CL2009001358A1 (es) Compuestos macrociclicos derivados de urea y derivados de sulfamida, inhibidores de la enzima tafia; proceso de preparacion de dichos compuestos; y su uso para la prevencion y tratamiento de trastornos asociados con trombosis, embolias, hipercoagulabilidad o cambios fibroticos.
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
MA33894B1 (fr) Procedes d&#39;administration therapeutique de la pirferidone
TR201900259T4 (tr) Heterosiklik Bileşikler Ve Bunların Kullanımları
JO3002B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
TR201819092T4 (tr) Serin proteaz inhibitörleri olarak multi-sübstüte edilmiş aromatik bileşikler.
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
CU20130115A7 (es) Compuestos y composiciones como inhibidores de trk
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA200970666A1 (ru) Трициклические соединения, композиции и способы
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
BR112014002675A2 (pt) &#34;quinazolina como inibidores de serina/treonina quinase, seus usos, e composição&#34;
ECSP066941A (es) DERIVADOS DE IMIDAZOL UTILIZADOS COMO INHIBIDORES DE TAFIa
EA201200118A1 (ru) Дифференцировка мезенхемальных стволовых клеток
PE20160934A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolisis
CL2011002911A1 (es) Compuestos derivados de benzamidas, inhibidores de serina proteasa; composición farmacéutica; uso del compuesto para tratar cáncer.
NO20084301L (no) Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler
BR112018008506B8 (pt) Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos
EA200970662A1 (ru) Трициклические соединения и их применение в качестве модуляторов глюкокортикоидного рецептора
NO20092246L (no) Urea og sulfamidderivater som tafiainhibitorer